New drug targets Hard-to-Treat cancer mutation in first human trial
NCT ID NCT07023731
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that dose in people with advanced pancreatic cancer. About 159 participants will receive the drug intravenously.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ARV-806 (a drug that breaks down a specific mutated protein in cancer cells)
- What this could lead to
- If it works, this could point toward a new treatment option for advanced cancers with a specific KRAS mutation, especially pancreatic cancer.
- What could go wrong
- This is the first time ARV-806 is tested in humans, so safety and effectiveness are unknown. The trial is small and early-stage, so results may not lead to a widely available treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Trial Site
Phoenix, Arizona, 85004, United States
-
Clinical Trial Site
Phoenix, Arizona, 85054, United States
-
Clinical Trial Site
New Haven, Connecticut, 06510, United States
-
Clinical Trial Site
Tampa, Florida, 33612, United States
-
Clinical Trial Site
Indianapolis, Indiana, 46250, United States
-
Clinical Trial Site
Grand Rapids, Michigan, 49546, United States
-
Clinical Trial Site
New York, New York, 10032, United States
-
Clinical Trial Site
New York, New York, 10065, United States
-
Clinical Trial Site
Huntersville, North Carolina, 28078, United States
-
Clinical Trial Site
Cleveland, Ohio, 44106, United States
-
Clinical Trial Site
Houston, Texas, 77030-7009, United States
-
Clinical Trial Site
San Antonio, Texas, 78229, United States
-
Clinical Trial Site
Salt Lake City, Utah, 84112, United States
-
Clinical Trial Site
Fairfax, Virginia, 22031, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Can your own immune cells beat advanced cancer?
- Blood and gut clues may flag pancreatic cancer risk early
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill outsmart Tumors' defenses?